Volume 32, Issue 213 (10-2022)                   J Mazandaran Univ Med Sci 2022, 32(213): 42-54 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shokrzadeh M, Shaki F, Amani N. Effect of Clarithromycin on Enhancement of Doxorubicin-induced Cytotoxicity and Apoptosis in A549 Tumor-Cell Line. J Mazandaran Univ Med Sci 2022; 32 (213) :42-54
URL: http://jmums.mazums.ac.ir/article-1-18070-en.html
Abstract:   (715 Views)
Background and purpose: Nowadays, multi-drug regimens or combination therapy are new approaches in cancer treatment that combine two or several therapeutic agents. Combination therapy aims at improving the therapeutic efficacy of anticancer drugs while reducing toxicity and preventing drug resistance. The aim of this study was to determine the synergistic effect of combined clarithromycin and doxorubicin in lung cancer A549 cell line.
Materials and methods: Combined cytotoxicity of doxorubicin and clarithromycin was evaluated by MTT assay in A549 cell line. The nature of the interaction observed between doxorubicin and clarithromycin was analyzed in Compusyn software based on Chou and Talalay method. In order to clarify the molecular mechanism of the drug synergism, apoptosis was measured by Annexin V/PI double staining.
Results: Clarithromycin at 500 µM synergistically reduced the IC50 value of doxorubicin. The enhanced cytotoxicity of doxorubicin by clarithromycin was associated with increased apoptotic cell death in A549 cell line.
Conclusion: Clarithromycin is a suitable candidate when combined with other anticancer drugs in vitro. However, more investigations are needed to evaluate the application of clarithromycin in adjuvant cancer therapy.
Full-Text [PDF 749 kb]   (371 Downloads)    
Type of Study: Research(Original) | Subject: toxicology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb